Get started
Author

Silke Hoersch

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
2017 · Véronique Diéras, David Miles, et al. · The Lancet Oncology · 666
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
2017 · Ian E Krop, Sung-Bae Kim, et al. · The Lancet Oncology · 530
Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure
2004 · Franz Hartmann, Milton Packer, et al. · Circulation · 301
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial
2015 · Hans-Joachim Schmoll, Josep Tabernero, et al. · Journal of Clinical Oncology · 291
PDF
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
2019 · Edith A. Perez, Carlos Barrios, et al. · Cancer · 112
PDF
NT-proBNP in Severe Chronic Heart Failure: Rationale, Design and Preliminary Results of the COPERNICUS NT-proBNP Substudy
2004 · Franz Hartmann, Milton Packer, et al. · European Journal of Heart Failure · 91
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
2015 · Joyce O'Shaughnessy, Hartmut Koeppen, et al. · Clinical Cancer Research · 62
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer
2019 · Manish A. Shah, Yoon-Koo Kang, et al. · Gastric Cancer · 53
PDF
Population pharmacokinetics and exposure–response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2‐targeted regimens
2017 · Shang‐Chiung Chen, Angelica Quartino, et al. · British Journal of Clinical Pharmacology · 22
PDF
Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).
2012 · Hans-Joachim Schmoll, Josep Tabernero, et al. · Journal of Clinical Oncology · 22
Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer
2011 · A.U. Buzdar, B. Xu, et al. · Annals of Oncology · 13
Role of tumor infiltrating lymphocytes (TILs) in HER2+ metastatic breast cancers (MBC) treated with trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine (L+C) (EMILIA Trial).
2016 · Sunil S. Badve, Yesim Gokmen-Polar, et al. · Journal of Clinical Oncology · 10
Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE.
2017 · Edith A. Perez, Carlos H. Barrios, et al. · Journal of Clinical Oncology · 9
The role of TP, TS, and DPD as potential predictors of outcome following capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Biomarker findings from study NO16968 (XELOXA).
2012 · Hans-Joachim Schmoll, Josep Tabernero, et al. · Journal of Clinical Oncology · 4
Course of HIV disease does not depend on risk group: 7.5-year follow-up in 296 patients
2003 · Ulrich R Hengge, Barbara Franz, et al. · International Journal of STD & AIDS · 3
Influence of creatinine on plasma concentrations and the prognostic value of N-terminal pro-BNP in severe chronic heart failure: Data from a substudy of the COPERNICUS trial
2003 · Franz S. Hartmann, Iidiko Amann-Zalan, et al. · Journal of the American College of Cardiology · 1
PDF
Supplementary Tables S1-5 from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
2023 · Joyce O'Shaughnessy, Hartmut Koeppen, et al.
Supplementary Figure 3 from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
2023 · Joyce O'Shaughnessy, Hartmut Koeppen, et al.
Supplementary Figure 2 from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
2023 · Joyce O'Shaughnessy, Hartmut Koeppen, et al.
Supplementary Figure 1 from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
2023 · Joyce O'Shaughnessy, Hartmut Koeppen, et al.
Data from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
2023 · Joyce O'Shaughnessy, Hartmut Koeppen, et al.
Data from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
2023 · Joyce O'Shaughnessy, Hartmut Koeppen, et al.
Supplementary Tables S1-5 from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
2023 · Joyce O'Shaughnessy, Hartmut Koeppen, et al.
Supplementary Figure 2 from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
2023 · Joyce O'Shaughnessy, Hartmut Koeppen, et al.
PDF
Supplementary Figure 1 from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
2023 · Joyce O'Shaughnessy, Hartmut Koeppen, et al.
PDF
Works count: 29
Citation count: 2,190
H-index: 11
I10-index: 12
Year
Topic
Type